SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam Treatment
Simufilam 100 mg and 50 mg Reduced Plasma Levels of Altered Filamin A in Alzheimer’s Patients 48% (p=0.003) and 44% (p=0.02) Respectively
Plasma Results with SavaDx Track Plasma Results with p-Tau181
Plasma Data Provide Evidence of Target Engagement
Poster Presentation at AAIC Today
About Today’s Poster Presentation at AAIC
Scientists for Cassava Sciences will show a poster presentation titled, “SavaDx, a Novel Plasma Biomarker to Detect Alzheimer’s Disease, Confirms Mechanism of Action of Simufilam” at the Alzheimer’s Association International Conference (AAIC) in Denver, CO and virtually. Cassava Sciences’ AAIC poster presentation with SavaDx can be accessed on the ‘Investors’ page of the Company’s website: https://www.CassavaSciences.com
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.